Production (Stage)
Stoke Therapeutics, Inc.
STOK
$9.43
$0.252.72%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 1,176.88% | 60.34% | -2.86% | 2.57% | 2.17% |
| Total Depreciation and Amortization | -9.32% | -2.59% | -1.46% | -2.66% | -9.78% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.17% | -7.70% | -2.36% | 29.72% | -9.51% |
| Change in Net Operating Assets | 157.56% | -522.14% | -10,710.00% | 99.36% | -436.11% |
| Cash from Operations | 668.39% | -7.30% | -23.68% | 28.86% | -18.97% |
| Capital Expenditure | -261.90% | 59.22% | -123.91% | -283.33% | 94.76% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1,500.93% | 102.88% | 66.11% | -982.32% | -33.33% |
| Cash from Investing | 1,564.47% | 102.73% | 66.01% | -983.84% | -32.38% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 141.90% | -93.04% | -93.24% | 6,926.79% | -76.62% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 141.90% | -93.04% | -93.24% | 6,926.79% | -76.62% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 773.36% | 49.83% | -391.78% | 215.82% | -977.88% |